The proposed research plan involves the development of new drugs for the treatment of human breast cancer. We plan to design small molecule ligands to target the promoter and enhancer elements of-the Her-2/neu oncogene and other genes that encode proteins involved in breast cancer proliferation. Since overexpression and/or mutation of Her-2/neu is correlated with a poor prognosis in breast and ovarian carcinomas, downregulation of the Her-2/neu gene (and protein) may prove effective in combination therapy for these cancers. Synthetic pyrrole-imidizole (Py-lm) polyamides have been shown to bind a wide range of DNA sequences with subnanomolar affinities; moreover, these molecules can inhibit transcription factor-DNA interactions and gene expression both in vitro and in cultured cells. A series of Py-Im polyamides will be designed and synthesized to target the region immediately flanking the TATA and CCAAT box elements and the binding sites for Sp1, AP-2, ESX, and RBPJkappa within the promoter and proximal enhancer of the human Her-2/neu oncogene. Using DNase footprinting methods and gel mobility shift assays, we will determine whether these polyamides inhibit binding of the TATA-box binding protein, TBP, to the Her-2/neu TATA element and other transcription factors to their cognate sites in this promoter. The effects of the polyamides on basal and activated transcription will be monitored using cell-free extracts from breast carcinoma cells and transcription assays with purified factors and RNA polymerase II. We will monitor the effects of the polyamides, individually and in combination, on Her-2/neu mRNA expression in human breast carcinoma cell lines. The levels of Her-2/neu protein in polyamide-treated and control cells will be monitored by Western blotting with a monoclonal antibody to Her-2/neu. The effects of down-regulation of Her-2/neu mRNA and protein levels on cell viability, cellular motility and tumorogenicity will be monitored in both cell-based assays and in small animal models. Toxicity of the polyamides will be assessed in cell-based assays and non-specific effects of the polyamides on genome-wide gene expression will be monitored using high density DNA array/hybridization methodology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA084192-01
Application #
6038523
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Lees, Robert G
Project Start
1999-12-22
Project End
2002-11-30
Budget Start
1999-12-22
Budget End
2000-11-30
Support Year
1
Fiscal Year
2000
Total Cost
$336,888
Indirect Cost
Name
Scripps Research Institute
Department
Type
DUNS #
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Gearhart, Micah D; Dickinson, Liliane; Ehley, Jennifer et al. (2005) Inhibition of DNA binding by human estrogen-related receptor 2 and estrogen receptor alpha with minor groove binding polyamides. Biochemistry 44:4196-203
Shadel, William G; Stein, Michael D; Anderson, Bradley J et al. (2005) Correlates of motivation to quit smoking in methadone-maintained smokers enrolled in a smoking cessation trial. Addict Behav 30:295-300
Dudouet, Brigitte; Burnett, Ryan; Dickinson, Liliane A et al. (2003) Accessibility of nuclear chromatin by DNA binding polyamides. Chem Biol 10:859-67